<DOC>
	<DOC>NCT01792479</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Males or females at least 18 years of age Diagnosis of NSCLC with locally advanced or metastatic disease Previously treated with one platinumbased chemotherapy Disease status must be that of measurable and/or evaluable disease Performance status of 0 to 1 on the ECOG Scale Prior chemotherapy completed at least 3 weeks prior to study enrollment Prior radiation therapy allowed to &lt; 25% of the bone marrow Patient compliance and geographic proximity that allow adequate followup Adequate organ function Patients with reproductive potential must use contraceptive methods Signed informed consent from patient Active infection Pregnancy or planning to become pregnant Breast feeding Serious concomitant systemic disorders Second primary malignancy Patients who are symptomatic from brain metastasis Presence of detectable (by physical exam) thirdspace fluid collections More than 1 prior cytotoxic chemotherapy regimen for advanced disease Prior treatment with docetaxel History of severe hypersensitivity reaction to polysorbate 80 Peripheral neuropathy at study entry Patients known to be HIV positive Patients known to be seropositive for hepatitis C hepatitis B Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>lung cancer</keyword>
</DOC>